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Purpose: Metastasis to the pancreas is rare, and the benefit of resection for pancreatic metastasis is poorly defined. The aim of 
this study was to review our experiences of the operative management of metastasis to the pancreas. Methods: Between 1995 
and 2009, 11 patients (8 men and 3 women; median age, 54 years) were admitted to our institution with a metachronously 
metastatic lesion to the pancreas and later underwent pancreatic resection. The clinical features and outcomes of treatments 
were examined. Results: The primary cancers were renal cell carcinoma (RCC, n = 7), carcinoid tumor (n = 2), rectal cancer 
and leiomyosarcoma. Six patients underwent distal pancreatectosplenectomy, 3 pancreaticoduodenectomy and 2 patients 
underwent enucleation for small RCC. One patient died of metastatic RCC at 53 months after surgery and ten patients re-
main alive; four patients without disease at 7 to 69 months postoperatively, and the other six with disease at 11 to 68 months. 
Median postoperative survival of all patients was 34 months. Conclusion: Patients with a low surgical risk should be consid-
ered for pancreatic metastasectomy if curative resection is possible. Primary cancer type, which is associated with survival 
benefit, would be the best candidate for surgical resection of metastases to the pancreas.
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INTRODUCTION
The vast majority of pancreatic tumors are primary, and 
metastatic tumors of the pancreas are rare, although direct 
invasion from advanced cancers in neighboring organs is 
sometimes observed. Metastatic tumors in autopsy series 
have been reported in from 3% to 11% [1,2]. Furthermore, 
the majority of patients with pancreatic metastasis have 
widespread disease [3]. Metastatic disease to the pancreas 
has been only infrequently diagnosed in living patients. 
Furthermore, although surgical resection of metastatic le-
sions to the liver, lungs, and brain have been shown to im-
prove survival and quality of life, the optimal manage-
ment of pancreatic metastasis has not been clearly deline-
ated. However, over the past few years, morbidity and 
mortality improvements after surgical resection of the 
pancreas have enabled patients with metastatic disease to 
be treated with radical intent [4,5]. Here, we report our ex-
periences of eleven patients who underwent pancreatic re-
section for metastasis to the pancreas.Surgical resection of metastasis to the pancreas
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Table 1. Clinical findings of eleven patients with metastasis to the pancreas
Patients
Age
(yr)
Sex Diagnosis
Primary 
treatment
Intervals between 
primary tumor and 
metastases (mo)
Symptoms Site
No. of 
tumors
Extrapancreatic
disease
 1 59 M Renal cell carcinoma Nephrectomy  180 Neck mass Tail Multiple Thyroid 
 2 75 M Renal cell carcinoma Nephrectomy  118 Dizziness Tail Solitary − 
 3 66 M Renal cell carcinoma Nephrectomy   99 Asymptomatic Head Solitary −
 4 56 M Renal cell carcinoma Partial nephrectomy   64 Asymptomatic Body Multiple  Local recur
 5 66 F Renal cell carcinoma Nephrectomy   14 Asymptomatic Tail Solitary −
 6 54 M Renal cell carcinoma Nephrectomy    31 Asymptomatic Body Solitary −
 7 51 M Renal cell carcinoma Nephrectomy   46 Asymptomatic Head, body Solitary −
 8 35 M Carcinoid tumor Thymectomy 108 Asymptomatic Head, body Multiple  Mediastinum
 9 48 F Carcinoid tumor Right hemihepatectomy   51 Asymptomatic Body Solitary  −
10 41 M Rectal cancer Low anterior resection   14 Asymptomatic Tail Solitary −
11 49 F Leiomyosarcoma Wide excision   50 Asymptomatic Head Solitary −
METHODS
Between January 1995 and March 2009, 11 patients un-
derwent pancreatic resection for a metastatic tumor to the 
pancreas at the Samsung Medical Center, Sungkyunkwan 
University School of Medicine. During the same period, 
1,181 pancreaticoduodenectomies, 73 total pancreatec-
tomies and 317 distal pancreatectomies, were performed 
for various pancreatic diseases. We excluded patients who 
underwent pancreatic resection because of direct involve-
ment of the gland by other abdominal tumors. All patients 
had a metachronous lesion and the pancreas was a site of 
metastasis at the time of resection. Primary tumors were 
reviewed to confirm diagnoses and to identify possible 
correlations with cancer type. Standard operative proce-
dures were adopted for resectable tumors: pylorus-pre-
serving pancreaticoduodenectomy for tumors in the head, 
and distal pancreatosplenectomy for tumors in the body 
or tail. Primary tumor histologies and treatments, times 
between primary operations and metastasis diagnoses, 
presenting symptoms, diagnostic tools, surgical treat-
ments, and perioperative morbidities and mortalities 
were evaluated, by conducting a retrospective review of 
medical records and by contacting patients directly. 
RESULTS
Median patient age was 54 years (range, 35 to 75 years), 
and 8 men and 3 women were included in the study. Of 
these 11 patients, 7 patients had been previously treated 
for renal cell carcinoma (RCC), 2 for a carcinoid tumor, 1 
for rectal adenocarcinoma, and 1 for leiomyosarcoma of 
the lower extremity. Details of clinical findings are sum-
marized in Table 1. 
The median time between primary surgery and a diag-
nosis of pancreatic metastasis was 51 months (range, 14 to 
180 months). Nine patients were asymptomatic and meta-
static lesions were discovered during follow-up. The 
symptomatic 2 patients experienced neck mass and dizzi-
ness 180, 118 months after nephrectomy for RCC, 
respectively. The patient with neck mass had 4.8 cm en-
hancing mass and the other patient had a 5.3 cm heteroge-
neously enhancing mass with an internal ill-defined 
low-density area in the pancreatic tail by computed to-
mography (CT). Of all patients, CT scans revealed a heter-
ogeneously enhancing pancreatic mass in 9 patients (7 
RCC and 2 carcinoid metastases) and a low density lesion 
in the remaining patients (rectal cancer and metastasis 
from leiomyosarcoma, respectively). 
Two patients with carcinoid metastasis underwent 18- 
fluorodeoxyglucose positron emission tomography (FDG 
PET) and achieved a positive finding. One patient showed 
another region of increased focal uptakes by 18-FDG in the 
pancreatic head and uncinate process, which were not de-
tected by CT, but which were confirmed by endoscopic 
ultrasonography.
Three patients showed evidence of concurrent ex-Dong Do You, et al.
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Table 2. Surgical treatment and follow-up survivals
Patients
Preoperative 
diagnosis
Operation
Associated 
procedure
Tumor 
size (cm)
Adjuvant 
therapy
Follow-up Status
Survival
(mo)
 1 Metastasis Distal pancreatectomy Thyroidectomy 4.8 Immunotherapy Brain metastasis Alive 68
 2 Pancreatic endocrine Distal pancreatectomy − 5.0 − Lung metastasis Dead 53
  tumor
 3 Metastasis PPPD − 3.2 − Liver, lung metastasis Alive 12
 4 Metastasis Distal pancreatectomy Wide excision 3.0 − Right adrenal, Alive 32
    lung metastasis
 5 Metastasis Distal pancreatectomy − 4.0 Immunotherapy Lung metastasis Alive 34
 6 Metastasis Enucleation − 0.9 Chemotherapy Disease free Alive 7
 7 Metastasis Enucleation − 1.3 Immunotherapy Disease free Alive 69
 8 Metastasis Total pancreatectomy Mediastinal mass  8.5 − Local recurrence Alive 11
excision
 9 Metastasis Distal pancreatectomy − 1.5 − Disease free Alive 12
10 Pancreatic cancer Distal pancreatectomy − 2.2 − Disease free Alive 30
11 Cystic tumor PPPD − 4.0 Radiotherapy Lung metastasis Alive 21
PPPD, pylorus-preserving pancreaticoduodenectomy.
trapancreatic disease (2 RCC and 1 carcinoid). The patient 
with carcinoid tumor had a mass about 10 × 6 cm in the an-
terior mediastinum. Percutaneous fine needle biopsies of 
the mediastinal and pancreatic masses were performed 
and returned a diagnosis of metastatic carcinoid. The one 
patient with RCC, who had previously undergone partial 
nephrectomy for right RCC, had 2 metastatic lesions, in 
the posterior of pancreatic body and in the tail of the pan-
creas, respectively, according preoperative imaging studies. 
After exploration, however, the mass in the posterior of 
pancreatic body was found to be extrapancreatic. The oth-
er patient with RCC visited other hospital due to neck 
mass and underwent unilateral thyroidectomy, which 
pathologic diagnosis was clear cell carcinoma from RCC. 
After referral to our institution and work up for systemic 
spread of RCC, another lesion was detected in the tail of 
the pancreas by CT. These 3 patients underwent surgical 
resection for multiple metastases due to the treatment 
principle of the primary tumor with metastatic lesion. 
Before surgery, 8 of the 11 patients had a high clinical 
suspicion of a metastatic lesion. In the other three patients 
with RCC, rectal cancer, and leiomyosarcoma, metastatic 
tumors were initially misdiagnosed as pancreatic endo-
crine tumor, primary pancreatic carcinoma and cystic tu-
mor, respectively. One patient with rectal cancer received 
concurrent chemoradiotherapy after primary surgery, and 
one patient with leiomyosarcoma in the right inguinal 
area underwent radiotherapy due to a positive resection 
margin after wide excision. 
In 9 patients, tumors were resected with curative intent 
and enucleation was performed in 2 patients because 
metastatic tumor was small and exophytic. Pancreatico-
duodenectomy was performed in three patients including 
total pancreatectomy, and distal pancreatosplenectomy 
was performed in the other 6. In the patient with a media-
stinal mass, wide excision of the tumor was combined 
with pancreatic resection. There was no perioperative 
death. Postoperative complications occurred in 3 patients: 
two experienced a postoperative pancreatic fistula (POPF) 
of grade A and B, as defined by the International Study 
Group of Pancreatic Surgery, and the other POPF of grade 
B and an intra-abdominal abscess. The former resolved 
with conservative treatment and the latter was treated 
with percutaneous drainage. In all 11 cases, pancreatic 
metastases had the same histopathologic features as pri-
mary tumors; median tumor size was 3.2 cm (range, 0.9 to 
8.5 cm).
One patient died of metastatic RCC at 53 months 
postoperatively. Ten patients remain alive: four patients 
with a disease-free status at 7 to 69 months postopera-
tively, and the other six with disease at 11 to 68 months 
(Table 2). Median postoperative survival of 11 patients 
who all underwent surgery for metastatic pancreatic le-
sions was 34 months (range, 7 to 69 months).Surgical resection of metastasis to the pancreas
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DISCUSSION
Metastatic lesions to the pancreas are uncommon, and 
account for less than 2% of all pancreatic malignancies. 
The tumors that metastasize most frequently to the pan-
creas are renal cell carcinoma, melanomas, sarcoma, and 
colon, lung, and breast cancer [1,2,6]. Although pancreatic 
metastasis is rare, high volume centers will encounter pa-
tients with resectable metastatic disease. Reddy et al. [7] 
reported on 49 patients that underwent pancreatic re-
section for metastases from 1970 to 2007, which is the larg-
est single institutional series on pancreatic resection for 
metastatic nonpancreatic cancers. At our center, 11 (0.7%) 
of 1,571 pancreatic resections were performed for meta-
static tumors of the pancreas, which appears to be low 
compared with other series [1,2,5,8]. The symptoms of 
pancreatic metastases are frequently non-specific and sub-
tle, therefore pancreatic metastases are often found during 
regular surveillance imaging for primary cancers. Reddy 
et al. [7] reported that 45 of 49 patients (92%) had symp-
toms of abdominal pain, jaundice, weight loss, whereas 
another study reported that 6 of 13 patients (46%) were 
asymptomatic [2]. In our series, 9 of 11 patients (82%) were 
asymptomatic.
The preoperative differential diagnosis between a pri-
mary pancreatic neoplasm and a metastatic tumor may be 
problematic. Palmowski et al. [9] showed that unlike pan-
creatic adenocarcinoma, secondary pancreatic cancers 
usually show arterial phase enhancement on contrast- en-
hanced CT scans. Furthermore, unlike pancreatic adeno-
carcinoma, metastatic pancreatic lesions from RCC, color-
ectal cancer, and breast cancer tend to be rim-enhanced. In 
the present study, 9 metastatic lesions from 7 RCC and 2 
carcinoid tumor were rim-enhanced or heterogeneously 
enhanced, whereas the other 2 lesions from rectal cancer 
and leiomyosarcoma were not. Furthermore, in order to 
avoid major surgery, accurate preoperative staging must 
be done in patients with widespread disease [3,4,10,11], 
and 18-FDG-PET has proven to be useful in this context 
[5,12]. Our patient with a metastatic carcinoid tumor in the 
mediastinum and pancreas was found to have two other 
lesions by 18-FDG-PET, which were not detected by CT, 
but which were finally confirmed by endoscopic ultra-
sonography. Percutaneous and endoscopic fine-needle bi-
opsies may help establish a pathological diagnosis when a 
metastatic tumor is not amenable to surgery, but may be 
treated with chemotherapy. 
The time between diagnosis of primary cancer and the 
detection of pancreatic metastasis varies widely, and in 
particular, renal cell cancers are associated with a pro-
longed disease-free interval [4,6,13]. In the present study, 
the median time between primary disease and metastasis 
diagnoses for the renal cell cancer patients was 64 months 
(range, 14 to 180 months), and for the other patients was 
50.5 months (range, 14 to 180 months). 
Surgical resection of metastatic tumors to the pancreas 
should be approached by carefully applying appropriate 
selection criteria, because of the substantial morbidity as-
sociated with pancreatic resection and the questionable 
benefit of resection for pancreatic metastasis. Reddy and 
Wolfgang [14] in a systemic review of the literature, eval-
uated 243 patients who had undergone radical pancreatic 
resection for metastatic disease, and concluded that the ef-
fectiveness of pancreatic resection for metastatic tumor is 
dependent on the tumor biology of the primary cancer. 
RCC was found to be associated with best outcome, 
whereas lung cancer predicted the worst. Of their 243 pa-
tients, 193 (80%) had RCC, 19 colon cancer, 12 melanoma, 
and 12 sarcoma: median survivals and 5-year survival 
rates of patients with metastatic RCC were 8.75 years and 
66%; those of patients with metastatic colorectal cancer 
were 54 months and 27%; those of patients with metastatic 
sarcoma 40 months and 14% and median survival of pa-
tients with metastatic melanoma 14 months. We could not 
estimate 5-year survival in our cohort because there were 
only 11 patients. Reddy and Wolfgang [14] also suggested 
criteria for patient selection, namely, a primary cancer type 
associated with a good outcome, control at the primary 
cancer site, isolated metastases, resectability of metastasis, 
and the patient’s ability to tolerate pancreatic resection. 
Though 2 patients with RCC and one patient with carci-
noid had a extrapancreatic disease in the present study, 
metastasectomy was performed and these 3 patients were 
alive at the end of the study. It is difficult to conclude that 
surgical resection of multiple metastasis will provide sur-
vival benefit. It may be reasonable to follow the treatment Dong Do You, et al.
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principle of the primary tumor when multiple metastasis 
was recognized. 
Originally, radical nephrectomy was the gold standard 
for RCC without metastasis. However, the increase in 
small renal tumors incidentally found at earlier stages has 
lead to organ preserving surgery which been more fre-
quently preferred to radical nephrectomy for tumors less 
than 4 cm in diameter and limited to the kidney. For small-
er tumors (＜  2 cm in diameter), simple enucleation, dis-
secting around the pseudocapsule of the tumor, can be ap-
plied [15]. Similarly, we assumed that the biology of pri-
mary tumor would be same as if metastasis is solitary and 
the size is small. Therefore, metastatic RCC to the pancreas 
less than 2 cm in diameter that was not close to a main pan-
creatic duct can be a good indication for organ preserving 
pancreatectomy such as enucleation. In our series, 2 pa-
tients with metastatic RCC smaller than 2 cm underwent 
enucleation and has been disease-free status at 7, 69 
months postoperatively. However, further studies in or-
gan preserving pancreatectomy for small metastatic RCC 
are necessary. 
Since our study has the limitation of small sample size, 
heterogeneity of the primary tumor, some combination of 
adjuvant therapy and retrospective design, it might be dif-
ficult that surgical resection of pancreatic metastases 
would provide survival benefit. Additional follow up of 
our cohort and more experience of surgical resection for 
pancreatic metastasis would clarify these limits. 
In conclusion, patients with a low surgical risk should 
be considered for pancreatic metastasectomy if curative 
resection is possible. Careful selection of patients under-
going pancreatic resection for metastatic disease should be 
based on the primary cancer type which is associated with 
survival benefit after metastasectomy. 
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